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 EM1 and UVB1 reduce the viability of cells derived from HER2-positive 
and TNBC PDXs  
 UVB1 has antiproliferative actions in Trastuzumab-emtansine (T-DM1) 
resistant cells  
 UVB1 impairs the organoids formation capacity in T-DM1 resistant cells  
 UVB1 inhibits the growth of established organoids derived from T-DM1 
resistant cells  














Despite advances in breast cancer (BC) treatment, its mortality remains high 
due to intrinsic or acquired resistance to therapy. Several ongoing efforts are 
being made to develop novel drugs to treat this pathology with the aim to 
overcome resistance, prolong patient survival and improve their quality of life. 
We have previously shown that the non-hypercalcemic vitamin D analogues 
EM1 and UVB1 display antitumor effects in preclinical studies employing 
conventional cell lines and animal models developed from these cells. In this 
work, we explored the antitumor effects of EM1 and UVB1 employing BC cells 
derived from patient-derived xenografts (PDXs), which are a powerful preclinical 
tool for testing new drugs. We demonstrated that the analogues reduced the 
viability of HER2-positive and Triple Negative BC-PDXs. Moreover, using an in 
vitro model of acquired resistance to Trastuzumab-emtansine, UVB1 displayed 
anti-proliferative actions under 2D and 3D culture conditions. It inhibited both 
formation and growth of established organoids. In addition, a direct correlation 
between UVB1 antitumor effects and VDR expression in PDXs was found. In 
conclusion, all the results reinforce the potential use of these vitamin D 
analogues as antitumor agents to treat HER2-positive and Triple Negative BC.  
 




 Breast Cancer (BC) is the most commonly diagnosed cancer and the leading 
cause of cancer death in women worldwide [1]. BC is curable in ~70–80 % of 
patients with early stage (non- metastatic) and treatable in advanced 
(metastatic) stage. Treatment options for metastatic BC disease are addressed 
to prolong survival and control symptoms with low treatment- associated toxicity 
to maintain or improve quality of life.  
Currently, treatment decisions are taken based on histological and molecular 









progesterone receptor (PR) are considered hormone receptor- positive BC and 
are treated with hormonal therapies. For those tumors that overexpress human 
epidermal growth factor receptor 2 (HER2), anti-HER2 therapies are available, 
including monoclonal antibodies (trastuzumab and pertuzumab), small molecule 
inhibitors (lapatinib, neratinib, and tucatinib) and antibody-drug conjugates 
(ADC) [2]. Trastuzumab emtansine (T-DM1) is an ADC composed of the 
humanized monoclonal antibody trastuzumab covalently linked to the 
microtubule-inhibitory agent DM1 [3]. T-DM1 has shown activity in patients with 
trastuzumab resistance [4,5]. Also, FDA has recently approved T-DM1 as 
adjuvant therapy in patients with HER2-positive early breast cancer who have 
residual invasive disease after neoadjuvant taxane- and trastuzumab-based 
treatment [6,7]. However, these strategies of treatment are ineffective for triple-
negative BC (TNBC), which does not express ER or PR and lacks HER2 
overexpression or amplification. Although TNBC patients respond to 
chemotherapeutic agents such as taxanes and anthracyclines better than other 
subtypes of BC, prognosis remains poor [8]. In addition, the development of 
resistance to BC therapies that are initially effective is commonly observed [9, 
10]. Therefore, the identification of novel compounds to treat BC is needed. 
Vitamin D Receptor (VDR), a nuclear transcription-regulating factor that 
belongs to the steroid hormone superfamily, is involved in cell growth and 
differentiation in normal and BC tissue. Calcitriol is the most active form of 
Vitamin D that binds to VDR. Despite antitumor properties of calcitriol reported 
with this compound, its clinical use is partly limited due to the risk of developing 
adverse effects, such as hypercalcemia, at the effective dose required for 
antitumor activity [11]. Therefore, VDR agonists with low calcemic activity which 
retain or even increase the calcitriol-anticancer properties are being developed. 
Our group has synthetized two novel non-hypercalcemic vitamin D analogues, 
UVB1 and EM1, that have demonstrated promising antitumor effects in 
preclinical studies employing cell lines cultured under 2-dimensional (2D) 
conditions and in vivo models generated from these cells [12,13,14,15,16].  
In the current work we focused on the study of the antineoplastic effects of 
UVB1 and EM1 on cells derived from patient-derived xenografts (PDXs) 









heterogeneity of BC tumors [17], being a powerful preclinical tool for testing new 
drugs. We demonstrated that the analogues reduced the viability of HER2-
positive and TN BC-PDXs. Interestingly, using an in vitro model of acquired 
resistance to T-DM1, we showed that UVB1 displays anti-proliferative effects in 
2D and 3D culture conditions. These results reinforce the potential use of these 
vitamin D analogues as antitumor agents to treat HER2-positive and TNBC.  
 
2. MATERIALS AND METHODS 
2.1. Chemicals and Reagents 
 EM1, UVB1 and calcitriol (Sigma-Aldrich, D1530) were reconstituted as 
previously described [12,13]. Briefly, they were dissolved in 100% HPLC-grade 
isopropanol (vehicle) and stored protected from light at –20°C. Compounds 
were diluted in the culture medium to reach the required concentrations to 
perform the assays. The maximal concentration of vehicle used in this study 
had no effect on cell viability.  
 
2.2. Cell culture  
All cells, except HCC1954 cell line, were cultured in Dulbecco’s Modified 
Eagle’s Media (DMEM)/F12 (Sigma) supplemented with 10 % (v/v) fetal bovine 
serum (FBS, Gibco), 1 % (v/v) L-glutamine (Gibco), 1 % (v/v) Penicillin / 
Streptomycin (Gibco,) at 37ºC with 5 % CO2 in humidified air atmosphere. 
HCC1954 cells were maintained in Roswell Park Memorial Institute (RPMI-
1640, Sigma) medium supplemented with 10 % FBS, L-glutamine, penicillin and 
streptomycin. HCC1954 (#CRL-2338) and SK-BR-3 (#HTB-30) were from the 
American Type Culture Collection. 
All cell cultures derived from PDXs were generated in Vall d’Hebron Institute 
of Oncology (VHIO). In vivo models were established with the approvals of the 
Vall d’Hebron University Hospital ethic committee and of the Ethical Committee 
for the Use of Experimental Animals at the VHIO. To this end, fragments of 
human BC tissues were implanted into the fourth fat pad of NOD.CB17-
Prkdcscid/J (NOD/SCID) mice. Depending on tumor size, one to two mice were 
employed per sample to implant the patient biopsies. When tumors reached 
1000 mm3, mice were sacrificed. Tumors were excised and cut into the smallest 









shaking at 80 rpm, washed and resuspended in DMEM/F12 supplemented with 
10 % FBS, L-glutamine and Penicillin/Streptomycin. 
PDX118 and PDX554 were generated from skin and brain metastatic BC 
tumor samples of a HER2-positive BC tumor, respectively. PDX410, PDX570, 
PDX575, PDX347, PDX454 and PDX549 were originated from a biopsy of the 
primary TNBC tumor. 
R200 is an in vitro model of acquired resistance to T-DM1. It was generated 
as previously described [18]. Briefly, PDX118 cells were continuously exposed 
to increasing concentrations of T-DM1 over a period of 3 months. The started 
concentration used was 20 ng/mL and it was progressively doubled every 10 
days until 200 ng/mL was achieved. This model was tested for resistance in 
vitro following a dose response study of T-DM1 for a recent review of the 
complete characterization of this in vitro resistant model, see [18]. 
 
2.3. Cell viability assays 
2.3.1. Crystal violet staining assays 
 Cells were seeded into 96-well plates in 100 µl of complete medium and 
treated as indicated in the corresponding figures. After the time of treatment, 
medium was removed and adherent cells were fixed in 10 % paraformaldehyde 
for 10 min, then washed thrice in distilled water and stained with 0.1 % crystal 
violet for 30 min. After washing, the stain was dissolved with 10% acetic acid 
and subsequently quantified with VICTOR3 Multilabel Plate Reader at 560 nm. 
Data obtained with crystal violet staining (optical density per well) were 
expressed as a percentage of control. The experiments were repeated at least 
twice and performed in triplicate.   
 
2.3.2. Automatic cell counting assays 
 The same number of viable PDX118 cells (3 × 105 cells) treated with UVB1 
or vehicle (10-7 M, 120 h) were seeded into 60 mm dishes and allowed to grow 
in complete medium without any stimuli. After 4 days, cell viability was 
measured by Vi-CELL XR automatic analyzer (Beckman Coulter). The 
experiments were performed in triplicate. 
 









 Human PDX118 parental and resistant cells treated with UVB1 (10-7 M) or 
vehicle during 96 h were collected, washed twice with ice-cold PBS, fixed with 
ice-cold 70% ethanol and preserved at -20°C at least 24 h. Then, cells were 
washed with PBS, stained with 50 μg/mL Propidium Iodide (PI, Roche) plus 
RNase A (100 µg/mL) and analyzed for DNA content by FACScan flow 
cytometry (Becton Dickinson) with Cell Quest software (Becton Dickinson, 
Heidelberg, Germany). At least 100,000 cells were analyzed for each sample 
and the experiment was performed in triplicate. 
 
2.5. Western blot analysis  
PDX118 parental cells treated with UVB1 or vehicle (10-7 M, 96 h) and cells 
derived from HER2-positive and TNBC PDXs cultured to 70–80% confluence 
were lysed in lysis buffer containing 2 % TRIS 1 M, 1 % Triton-X 100, 0.5 M 
EDTA 0.5 M, 2 % sodium chloride 1 M and protease inhibitors for 30 min on ice 
and centrifuged at maximal speed for 10 min at 4°C. Protein extracts were 
quantified by Bradford assay using a Jasco V-630 spectrophotometer. The 
same amount of protein was resolved by SDS–polyacrylamide gel 
electrophoresis and transferred to PVDF membranes (Millipore). Membranes 
were subsequently blocked with 2 % non-fat milk in PBS for 30 min at room 
temperature and further incubated at 4°C overnight with primary antibodies. 
Then, membranes were washed and incubated with the appropriate horseradish 
peroxidase (HRP)-conjugated secondary antibodies for 90 min at room 
temperature. Protein bands were visualized using the enhanced 
chemiluminescence (ECL) method. Representative blots from at least three 
independent experiments are shown in the figures. 
Primary antibodies recognizing human glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (#Ab128915, Abcam), Cyclin D1 (#92G2, Cell 
Signaling Technology), p21 (sc-397, Santa Cruz Biotechnology), p27 (#610241, 
BD Biosciences) and VDR (C-20, sc-1008, Santa Cruz Biotechnology) were 
used. As secondary antibodies, we used ECL rabbit IgG, HRP–linked whole 
antibody (from donkey, #NA934–1ML, Amersham GE Healthcare) and ECL 











2.6. CYP24A1 and VDR mRNA expression 
Cells derived from PDX118, R200 and PDX570 were treated with vehicle, 
UVB1, EM1 or calcitriol in triplicate (10-7 M, 96 h). Total RNA isolation from 
treated cells was performed as recommended by the supplier (RNeasy Mini Kit, 
Qiagen, Hilden, Germany) and mRNA was reverse-transcribed to cDNA by 
using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA, USA). Quantitative reverse transcription-polymerase chain 
reaction (qRT-PCR) was performed with Taqman primers (Applied Biosystems) 
for CYP24A1 (Hs00167999_m1), VDR (Hs01045843_m1) and GAPDH 
(Hs02758991_g1) using an ABI 7900HT Sequence Detection System. Each 
sample was assayed in triplicate. The CT (Cycle Threshold) values of the real-
time PCR were extracted from each assay with SDSv2.0 software tool (Applied 
Biosystems) and analyzed using DataAssist Software (Applied Biosystems) 
following the manufacturer’s instructions. CT values of target gene were 
normalized with the CT value of the housekeeping gene GAPDH and data were 
expressed relative to vehicle-treated cells. 
 
2.7. Organoid culture  
Organoids were generated using R200 cells in culture with complete medium 
DMEM/F12.  
On one hand, to evaluate the inhibition capacity of organoid formation by 
UVB1, single cells (5 x 103 or 5 x 104 cells/ well) were seeded into 48-well 
plates in drops of Matrigel (100 %, #354234, BD) and UVB1 or vehicle 
treatment (10-7 M) were added to culture medium. Medium was removed every 
two days and replaced by drugs treatment. After 7 or 14 days, culture medium 
was removed and wells containing organoids embedded in Matrigel were 
washed with PBS and trypsinized to disaggregate to single cells. Then, cell 
viability of each condition was measured by CellTiter-Glo® Luminescent Kit 
(Promega). This is a method to determine the number of viable cells based on 
quantitation of the ATP present, which is directly proportional to the number of 
cells present in the well. The experiments were repeated twice and performed in 









On the other hand, to evaluate UVB1 inhibition of established organoid 
growth, 1 x 103 R200 cells were seeded into 48-well plates in 100 % of Matrigel 
and allowed to grow until organoids formation (11 days). Then, they were 
treated with vehicle or UVB1 (10-7 and 10-6 M), changing the treatments every 
two days. After 14 days, organoids from each condition were trypsinized and 
counted by Fluorescence-activated cell sorting (FACS).  
 
2.8. Statistical analyses 
GraphPad Prism version 5.0 software (GraphPad Software, San Diego, CA, 
USA) was used for statistical analyses. Cell viability and cell cycle assays were 
analyzed with two-way Analysis of Variance (ANOVA) and Bonferroni post-
tests. The assays performed to evaluate the inhibition of the capacity of 
organoid formation and the growth of established organoids were analyzed by 
unpaired t-test and one-way ANOVA and Bonferroni post-test, respectively. The 
correlation coefficient was calculated using Pearson’s test based on the normal 
distribution of the variables. mRNA and protein expression were analyzed by 
one-way ANOVA and Bonferroni post-test. To establish whether or not each 
parameter group represented a Gaussian distribution, a D’Agostino–Pearson 
Omnibus normality test was applied. Results were considered to be statistically 
significant at a p< 0.05. 
 
3. RESULTS  
Vitamin D analogues UVB1 and EM1 reduce cell viability of human HER2-
positive BC cell lines. 
We had previously demonstrated that the analogues UVB1 and EM1 
decreased cell viability of cell lines coming from different tumor types (colon 
cancer, head and neck squamous cell carcinoma, glioblastoma multiforme) 
[12,13,15,16]. Additionally, EM1 displayed anti-metastatic effect [14] in an 
animal model developed from hormone-independent HER2-positive LM3 cell 
line, which is derived from a murine mammary adenocarcinoma [19]. Taking 
into account these previous results, we proposed to investigate the antitumor 
activity of these analogues in the viability of human HER2-positive BC cell lines 
and then on cells derived from PDXs cultured under 2D and 3D conditions. To 









HER2-positive BC cell lines, HCC1954 and SK-BR-3. As shown in Figure 1, 
UVB1 reduced the cell viability of both BC cells lines, while EM1 decreased the 
viability of SK-BR-3 cells only at the concentration of 10-6 M.  
 
 
Figure 1. Vitamin D analogues reduce cell viability of HER2-positive BC cell lines. 
Concentration-response curves obtained from cells exposed to vehicle, UVB1 or EM1 for 120 h 
and stained with crystal violet. The results were expressed as percentage of vehicle-treated 
cells. Data points represent mean ± SEM from three independent experiments. Two-way 
ANOVA and Bonferroni post-test was applied; **p<0.01 and ***p<0.001. 
 
Vitamin D analogues UVB1 and EM1 decrease the viability of cells derived 
from HER2-positive PDXs.  
In order to test the antitumor effects of the analogues on PDXs cell viability, 
and compare the effects with those obtained in cell lines, we performed viability 
assays using two different HER2-positive PDXs: PDX118 and PDX554 
generated from skin and brain metastatic BC tumor samples, respectively. As 
shown in Figure 2, the UVB1 analogue decreased the viability of both PDXs and 
EM1 only reduced the viability of PDX554 at 10-6 M (Figure 2 A and B). 
Also, we tested the effects of both analogues on R200 cells. These cells are 
an in vitro model of acquired resistance to T-DM1, the second-line therapy for 
HER2-positive BC [20]. It was generated from PDX118 that was chronically 
treated with increasing concentrations of T-DM1. Interestingly, we obtained 
similar findings compared to parental cells. The analogue EM1 did not affect the 
viability of R200 cells whereas UVB1 significantly reduced it (Figure 2 C and D).  
 































































































Figure 2. Vitamin D analogues exhibit antitumor effect on cells derived from HER2-
positive PDXs. Concentration-response curves obtained from A) PDX118, B) PDX554 and C) 
R200 cells exposed to vehicle, UVB1 or EM1 for 120 h and stained with crystal violet. D)  
Photograph of a 96-well plate stained with crystal violet at the end point. Wo: without treatment. 
The results were expressed as percentage of vehicle-treated cells. Data points represent mean 
± SEM from three independent experiments. Two-way ANOVA and Bonferroni post-test was 
applied; **p<0.01 and ***p<0.001. 
 
All cell viability results show that UVB1 has a potent antineoplastic effect on 
HER2-positive BC cells and PDXs, and a stronger effect than EM1. Therefore, 
we investigated the cellular mechanisms underlying the antitumor effect of 
UVB1 using PDX118 and R200 cells. To this end, we performed cell cycle 
analysis of propidium iodide-stained cells treated with UVB1 or vehicle. As 
depicted in Figure 3 A and B, an arrest of PDX118 cells in G0/G1 phase was 
observed after treatment with UVB1 (85.99 ± 1.10 % of UVB1-treated cells vs 
70.45 ± 3.57 % of vehicle-treated cells; ***p<0.001). Similar results were 
obtained with R200 cells, in which UVB1 analogue inhibited cell proliferation by 
an induction of cell cycle arrest in GO/G1 phase (83.04 ± 1.91 % of UVB1-










































































































































treated cells vs 75.74 ± 0.85 % of vehicle-treated cells; ***p<0.001). In 
concordance with cell cytometry results, a reduction of the cell cycle regulator 
Cyclin D1 expression was detected by Western Blot (Figure 3C), although no 
significant differences were observed in both p21 and p27 expression. As 
expected, EM1-treated cells showed the same levels of cyclin D1, p21 and p27 
than control cells (Supplementary Figure 1). 
 
Figure 3. UVB1 induces cell cycle arrest in HER2-positive BC cells derived from PDXs. A) 
Cell cycle analysis of PDX118 cells treated with UVB1 (10-7 M, 96 h) or vehicle. Cells were 
stained with PI and analyzed for DNA content with FACScan Calibur Becton Dickinson. Data 
points represent means ± SD from three replicates. ANOVA and Bonferroni post-test was 
applied, ***p<0.001 respect to vehicle. B) The table shows the percentage of PDX118 parental 
and R200 cells in each phase of cell cycle analyzed by flow cytometry. C) Western blot 
analyses to detect cyclin D1, p21 and p27 expression in PDX118 cells treated with UVB1 (10-7 




















Table 1. Analysis of cellular DNA content by flow cytometry
PDX118 Vehicle (%) UVB1 (%)
Sub GO/G1 1.15  0.95 0.31  0.21
GO/G1 70.45  3.57 85.99  1.10 (***)
S 8.96  1.90 4.27  2.02
G2/M 19.44  0.51 9.43  1.61
R200
Sub GO/G1 1.66  0.49 0.62  0.13
GO/G1 75.74  0.85 83.04  1.91 (***)
S 7.50  0.50 5.56  1.68





























































M) or vehicle for 96 h. The graph shows the densitometry of bands of at least three independent 
experiments. D) PDX118 cells were treated with vehicle or UVB1 (10-7 M, 120 h), seeded in 
culture dishes and allowed to grow to evaluate if the effect of the analogue on proliferation is 
maintained over time. The results were expressed as number of cells at the end of the 




Supplementary Figure 1. Western blot analyses to detect cyclin D1, p21 and p27 expression 
in PDX118 cells treated with UVB1, EM1 (10-7 M) or vehicle for 96 h. 
  
In order to test if the anti-proliferative effect of UVB1 on PDX118 cells was 
maintained in absence of the analogue, we seeded 3 x 105 cells pre-treated 
with UVB1 or vehicle in culture plates and allowed to growth in the absence of 
the compounds. After four days, cells were counted. We observed that control-
treated cells continued dividing (1,060,000 ± 113.14 cells) while analogue-
treated cells remained arrested (490,000 ± 98.99 cells) (Figure 3D). In fact, 
control-treated cells doubled 3.5 times while UVB1-treated cells did it 1.6 times 
in 4 days. This represents a 53.8 % of cell inhibition, suggesting that UVB1 anti-
proliferative effect maintains over time, at least, during four days after treatment.  
 
UVB1 impairs organoids formation capacity in T-DM1 resistant cells. 
When cells are placed within a hydrogel, often Matrigel, and in presence of 
suitable exogenous factors, the system mimics the tumor microenvironment 
present in vivo allowing cell-extracellular matrix interactions [21]. These 
characteristics make this model an attractive system to evaluate the antitumor 
















previous results that UVB1 exerted antitumor effect in TDM-1 resistant cells, we 
embedded R200 cells in Matrigel, in presence of UVB1 in the culture medium 
and allowed cells to grow for 7 (Figure 4A) or 14 (Figure 4B) days. Confirming 
the previous results obtained under 2D conditions, we observed a remarkable 
inhibition in the capacity of R200 cells to establish organoids at both 7 and 14 
days after UVB1 treatment. The percentage of inhibition was 57.58 ± 4.24 % at 
day 7 and 95.56 ± 0.51 % at day 14 after analogue treatment. Next, we tested if 
UVB1 could impair the growth of established organoids in order to mimic 
already established tumors in vivo. 
 
Figure 4. UVB1 reduces tumor formation capacity of R200 cells grown under 3D culture 
conditions. R200 single cells were seeded in Matrigel and treated with UVB1 (10-7 M) during A) 
7 days and B) 14 days. The kit CellTiter-Glo® was used to measure cell viability at the end of 
the treatment. Representative micrographs of the conditions are shown (x40). The assay was 
performed in triplicate. Unpaired t test was applied. **p<0.01; ***p<0.001.  
 
UVB1 inhibits the growth of established organoids generated from T-DM1 
resistant cells. 
We tested the effect of the analogue on established organoids obtained after 
10 days of seeding R200 cells in Matrigel. These structures were treated with 
vehicle or UVB1 at two concentrations (10-7 and 10-6 M). After 14 days of 
treatment, we detected a significant reduction in organoids growth at both 
CONTROL UVB1 
Time  0h:




































































concentrations tested, compared to control (UVB1 = 64.36 ± 15.75 % and 0.02 
± 0.03 % at 10-7 and 10-6 M, respectively; Figure 5).  
 
Figure 5. UVB1 inhibits the growth of established organoids of PDX118 T-DM1 resistant 
cells. Organoids obtained from R200 cells were treated with vehicle or UVB1 (10-7 and 10-6 M) 
during 14 days. The assay was performed in triplicate and the number of the cells were counted 
by FACS. The results were expressed as percentage of vehicle-treated cells. T0: initial day of 
organoids treatment. Representative micrographs of the conditions are shown (x40).  One way 
ANOVA and Bonferroni post-test was applied. *p<0.05; ***p<0.001. 
 
All these results demonstrate the ability of UVB1 to inhibit both organoids 
formation and its growth, reinforcing the potential use of this analogue for the 
treatment of T-DM1 resistant BC tumors. 
 
Vitamin D analogues UVB1 and EM1 reduce the viability of cells derived 
from TNBC-PDXs.  
A significant percentage of BC patients are grouped together as TNBCs. The 
main treatment for them remains chemotherapy, which usually has short-lived 
efficacy. Hence, it is critical to develop novel therapies for these patient 
population. Therefore, we decided to evaluate the effects of UVB1 and EM1 on 
the viability of cells derived from TNBC-PDXs. We treated a panel of six PDXs 





















We detected that both vitamin D analogues significantly reduced viability of 
TNBC-PDX cells (Figure 6). Specifically, EM1 decreased the viability in three 
out of six TNBC-PDXs (PDX410, PDX575 and PDX549), whereas UVB1 
reduced the viability of all the TNBC-PDXs tested. Collectively, these results 
suggest that vitamin D analogues could be a promising therapeutic option to 

































































































































































































































Figure 6. Vitamin D analogues decrease the viability of cells derived from TNBC-PDXs. 
Concentration-response curves obtained from cells derived from A) PDX410, B) PDX570, C) 
PDX575, D) PDX347, E) PDX454 and F) PDX549, exposed to vehicle, UVB1 or EM1 over a 
total period of 120 h and stained with crystal violet. The results were expressed as percentage 
of vehicle-treated cells. Data points represent mean ± SEM from at least two independent 
experiments. Two-way ANOVA and Bonferroni post-test was applied; *p<0.05, **p<0.01 and 
***p<0.001.  
 
Regarding the effects of the analogues compared to the natural hormone in 
these models, we performed viability assays including calcitriol as a positive 
control. We found that UVB1 was more potent than calcitriol in reducing the 
viability of HER2-positive PDX118, in both parental and resistant cells, and it 
displayed similar effect to calcitriol in the TNBC PDX570 (Supplementary Figure 
2). 
 
Supplementary Figure 2. UVB1 is more potent than calcitriol in reduce viability of cells 
derived from PDXs. Concentration-response curves obtained from A) PDX118, B) R200 and 
















































































































































violet. The results were expressed as percentage of vehicle-treated cells. Data points represent 
mean ± SEM from three independent experiments. Two-way ANOVA and Bonferroni post-test 
was applied; *p<0.05 and ***p<0.001. 
 
Relationship between analogues response and VDR expression  
Taking into account that calcitriol exerts its antitumor effects through VDR, 
we determined the VDR expression in PDXs used in this work to evaluate its 
correlation with the analogues antitumor response. As shown in Figure 7, VDR 
was expressed in all PDXs (Figure A and B), and a strong negative correlation 
was obtained between VDR expression and LogIC50 of UVB1 (r= -0.8985, p= 
0.001, Figure 7C). This means a direct correlation between VDR expression 
and response to UVB1. In fact, PDX570, the tumor that expresses the lowest 
protein level of VDR (Figure 7B), showed a very limited sensibility to UVB1 
(Figure 6B). No correlation was found for EM1 analogue. These data support 
that the antineoplastic effectivity of UVB1 is associated with VDR protein levels. 
In addition to this, we evaluated the transcription of two VDR target genes by 
the analogues or calcitriol (employed as a positive control) in PDX118, R200 
and PDX570. As shown in Figure 7D, UVB1 significantly upregulated the 
transcription of CYP24A1 gene, being this upregulation stronger in PDX118 and 
R200 than in PDX570. Also, UVB1 increased VDR mRNA levels in HER2-
positive cells (Figure 7E). Thus, the activation of VDR by UVB1 was higher in 
HER2-positive PDXs that exhibit high VDR expression than in TNBC PDX that 










Figure 7. VDR expression in HER2-positive and TNBC PDXs and its correlation with UVB1 
antitumor response. A) VDR expression in cells derived from different PDXs analyzed by 
western blot.  B) The graph shows the quantification of VDR expression. Each bar represents 
mean ± SEM from two independent experiments. C) The graph depicts the correlation between 
VDR expression and LogIC50 of UVB1 analyzed by Pearson’s test; ***p<0.001. D) Relative 
CYP24A1 mRNA expression and E) Relative VDR mRNA expression were determined by RT-
PCR in PDXs treated with vehicle, UVB1, EM1 and calcitriol (positive control) at 10-7 M during 
96 h. mRNA expression was normalized to GAPDH mRNA and expressed relative to vehicle-treated 
cells. Each bar represents mean ± SD from three independent determinations. One way ANOVA 
and Bonferroni post-test was applied; *p<0.05, **p<0.01, ***p < 0.001.  
 
4. DISCUSSION  

























































































































































































































































































































































In the present study we evaluated the effects of the non-hypercalcemic 
analogues UVB1 and EM1 on cells derived from PDXs, which are considered a 
powerful resource to test novel therapeutics options [22]. We demonstrated that 
the analogues display anti-cancer effects not only on conventional cell lines but 
also on primary tumor cells derived from PDXs. Importantly, we showed for the 
first time that UVB1 is effective to reduce the viability of resistant cells to T-
DM1, which is the second line of treatment clinically employed in HER2-positive 
metastatic BC [23]. Thus, this analogue could be an alternative therapeutic 
option for tumors that are initially resistant to chemotherapies or acquire it 
during treatment.  
As known, antitumor actions of calcitriol in different tissues, including breast 
tissue, are mediated by VDR [24] as it was demonstrated employing mammary 
tumor cells derived from VDR null mice [25]. In this study, we found that all cells 
derived from PDXs express this receptor. Moreover, despite of both compounds 
were effective in reducing cell viability of BC cells, there are differences 
between their antineoplastic actions. UVB1 was more potent than EM1 in that it 
inhibited the proliferation of both T-DM1 resistant HER2-positive and all tested 
TNBC cells. These differences could be explained by their binding affinities to 
VDR and, as a consequence, the activation of the receptor. We have previously 
demonstrated that both analogues display higher binding affinity to VDR than 
calcitriol [15,16] and, if we compare the total interaction energies of both 
analogues for VDR, UVB1-energy is higher than EM1-energy, demonstrating a 
higher UVB1-affinity to VDR. Taking these observations into account and the 
strong correlation between UVB1 antitumor effects and VDR expression as well 
as the upregulation of the VDR-target genes by UVB1 found in this work, UVB1 
could be more effective against tumors that express relatively low levels of 
VDR. This is interesting in the context that it was recently described that low 
VDR expression in breast tumor tissues is associated with more aggressive 
characteristics [26]. Thus, UVB1 can be considered as a new therapeutic option 
not only for chemotherapeutic resistant tumors but also for TNBC tumors that 
express low levels of VDR. 
Previously, we have shown that EM1 displays anti-proliferative and anti-
migratory effects in glioma cells, and these actions were dependent on the 









of PDXs and antitumor response of EM1 was not found. This lack of correlation 
could be due to the small amount of IC50 employed to the test since the 
analogue showed antitumor effects in 4 of the 9 PDXs used in this study. 
In addition to inter-tumor heterogeneity (between tumors across the patient 
population), intra-tumoral heterogeneity (between cells within a single tumor, 
and between a primary tumor and its associated metastases in a single patient) 
makes BC a heterogeneous collection of diseases that are difficult to treat 
[27,28]. Furthermore, the scenario can become more complex with the 
appearance of resistance to treatment. In this context, to our knowledge, this is 
the first work that studies the antitumor activity of calcitriol analogues employing 
PDXs and organoids, which are systems that retain the cellular heterogeneity 
present in BC. EM1 and UVB1 showed antineoplastic effects on established 
cancer cell lines and, also, such effects were maintained in these systems 
which retain a remarkable degree of biological, histological, genomic, 
transcriptomic, and biomarker fidelity with their tumors of origin [29]. It is 
noteworthy that the anti-proliferative effects of UVB1 found under 2D culture 
conditions were corroborated under 3D in vitro culture conditions by inhibiting 
the formation of organoids as well as the growth of established organoids. This 
suggests that the analogue could be used in different stages of BC treatment.  
In summary, our results propose new therapeutic agents for tumors that are 
difficult to treat, such as those resistant to anti-HER2 therapies and TNBC 
tumors.  
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